Jennifer L. Cruz, PharmD, BCBS

Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of plasma cells in the bone marrow. Over the past decade, MM survival time has increased substantially due to the development of novel treatments, such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and autologous stem-cell transplantation (ASCT). Although these advances have increased survival time, most patients die from refractory disease, propagating the need for effective treatments with longer remissions.

In November 2015, the FDA approved 2 monoclonal antibodies (mAbs) for the treatment of MM: daratumumab (Darzalex, Janssen) and elotuzumab (Empliciti, Bristol-Meyers Squibb). In April 2015, recruitment began for a phase 1 clinical trial evaluating the safety and efficacy of atezolizumab (Tecentriq), an anti-programmed death ligand-1 antibody, for use in MM.

Therapeutic Use, Dosing, and Administration

Daratumumab is FDA-approved in patients who have received at least 3 prior lines of chemotherapy or who are refractory to both a PI and an IMiD, whereas elotuzumab is indicated in patients who have received 1 to 3 prior chemotherapies. Both mAbs are dosed according to body weight and administered by intravenous infusion once weekly initially, with subsequent reduced frequency. For the first 8 weeks, daratumumab 16 mg/kg IV is administered weekly; after this time, dosage switches to every 2 weeks for the next 16 weeks and then every 4 weeks until disease progression.

In combination with lenalidomide and dexamethasone, elotuzumab 10 mg/kg IV is administered weekly for the first 2 cycles (28 days each), then every 2 weeks thereafter until disease progression. Due to the high risk for infusion reactions, patients should receive an IV corticosteroid, acetaminophen, and an oral antihistamine prior to therapy. If a reaction of grade 2 or greater occurs, the infusion should be interrupted and symptoms managed appropriately.

Hematopoietic cells, including MM cells, express CD38, a glycoprotein involved in cellular adhesion and signaling. Daratumumab is a humanized recombinant immunoglobulin G1 kappa (IgG1k) mAb that targets CD38 cells and inhibits the growth of tumor cells that express CD38 by inducing apoptosis. Hematopoietic cells also express high levels of a surface receptor known as SLAMF7, or CD319. As a human IgG1k immunostimulatory mAb, elotuzumab tags the SLAMF7 receptor on MM cells and activates natural killer cells to destroy the MM cells.

Daratumumab monotherapy in patients with treatment-refractory MM (SIRIUS) was an open-label, multicenter, phase 2 trial that evaluated the use of daratumumab 16 mg/kg in heavily pretreated patients with MM (n = 106). Patients 18 years or older were enrolled if they had received at least 3 prior lines of treatment with evidence of disease progression or had disease refractory to both a PI and an IMiD. Patients were excluded if they received anti-MM treatment within 2 weeks or ASCT within 12 weeks of day 1 of therapy. The primary endpoint was overall response rate (ORR [partial response (PR) + very good PR + complete response (CR) + stringent CR]). Progression-free survival (PFS) was included as a secondary endpoint. Notably, 87% of patients had received more than 3 previous lines of therapy (median = 5) and 95% were considered double refractory to a PI and an IMiD. An ORR of 29.2% was observed (95% CI, 20.8%-38.9%), and the median PFS was 3.7 months (95% CI, 2.8-4.6 months). No patients discontinued treatment due to drug-related adverse events (AEs).

Elotuzumab Therapy for Relapsed or Refreactory MM (ELOQUENT-2) is an open-label, multicenter, randomized phase 3 trial evaluating the efficacy of elotuzumab in patients with MM. The trial is ongoing and will continue until 427 deaths, the predetermined overall survival end point. It includes patients 18 years or older who have failed 1 to 3 prior treatments with documented disease progression (median = 2) and who are receiving lenalidomide and dexamethasone with elotuzumab (n = 321) or without elotuzumab (control group; n = 325). Co-primary endpoints include PFS and ORR (PR or better). At the time of interim analysis, 35% of the elotuzumab group and 20% of the control group were still receiving study treatment.

The 1-year and 2-year rates of PFS in the elotuzumab group were 68% (95% CI, 63%-73%) and 41% (95% CI, 35%-47%), respectively, compared with 57% (95% CI 51%-62%) and 27% (95% CI, 22%-33%) in the control group. The median PFS was 19.4 months (95% CI 16.6-22.2 months) in the elotuzumab group versus 14.9 months (95% CI, 12.1-17.2 months) in the control group (HR, 0.7; 

 <.001). The ORR was 79% in the elotuzumab group and 66% in the control group (OR, 1.9; 

 <.001). Notably, 65% of the elotuzumab group and 57% of the control group reported serious AEs.

Clinical trials evaluating the safety and efficacy of these mAbs in combination with other anti-MM agents are ongoing.

Although well tolerated in clinical trials, daratumumab and elotuzumab are associated with a few notable adverse reactions: infusion-related reactions (48% and 10%, respectively), fatigue (39% and 62%), pyrexia (21% and 20%), cough (21% and 34%), diarrhea (16% and 47%), constipation (15% and 36%), and upper respiratory tract infections (20% and 23%).

Daratumumab and elotuzumab have not been found to induce or inhibit any transporters or enzymes, so drug interactions are not expected.

Based on similar naming, daratumumab may be confused with denosumab or dinutuximab. Elotuzumab may be confused with daratumumab, eculizumab, or evolocumab.

Monoclonal antibodies may be a viable option for patients with refractory MM. Unfortunately, these agents have not been directly compared in clinical trials. Daratumumab may be used as monotherapy, and elotuzumab may be used in combination with lenalidomide and dexamethasone. Although effective, mAbs are expensive: the average wholesale prices are $540.00 for daratumumab 100 mg/5 mL, $2160.00 for daratumumab 400 mg/20 mL, $2131.20 for elotuzumab 300 mg/vial, and $2841.60 for elotuzumab 400 mg/vial. Future studies evaluating the use of these agents in varying combinations with other anti-MM agents may expand their current place in therapy.

, is an assistant professor of clinical education at UNC Eshelman School of Pharmacy.

 is a PharmD candidate at UNC Eshelman School of Pharmacy.

CDC. Hepatitis C FAQs for health care professionals. cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 6 January 2017.

Zepatier (elpasvir/grazoprevir) [product information]. Kenilworth, NJ: Merck; 2016

Epclusa (sofosbuvir/velpatasvir) [product information]. Foster City, CA: Gilead; 2016.

Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) [product information]. North Chicago, IL: AbbVie; 2016.

Scheel T, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 

 2013;19(7):837-849. doi: 10.1038/nm.3248.

FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. FDA website. www.fda.gov/Drugs/DrugSafety/ucm522932.htm. Released October 4, 2016. Accessed February 5, 2017.

Viekira Pak [package insert]. North Chicago, IL: AbbVie; 2015.

Zezeum S, Ghalib R, Reddy KR, et al. Grazoprevir—elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial. 

Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. 

2015;386:1537-1545. doi: http://dx.doi.org/10.1016/S0140-6736(15)00349-9.

Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection. 

 2015; 373:2599-2607. doi: 10.1056/NEJMoa1512610. 

Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618-2628. doi: 10.1056/NEJMoa1512614.

American Association for the Study of Liver Disease; Infectious Diseases Society of America. AASLD/IDSA Guidelines. hcvguidelines.org

Articles

Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of plasma cells in the bone marrow.